GENinCode UK Ltd. (GB:GENI) has released an update.
GENinCode Plc, a UK-based predictive genetics company, will present its final results for 2023 on June 3, 2024, followed by a live investor presentation the next day. Specializing in cardiovascular disease and ovarian cancer risk assessment, the company emphasizes the importance of early detection and prevention through its advanced diagnostic technology. Their ROCA test for ovarian cancer has received recognition from NICE, highlighting the company’s commitment to innovative healthcare solutions.
For further insights into GB:GENI stock, check out TipRanks’ Stock Analysis page.
